GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Change In Receivables

Amoy Diagnostics Co (SZSE:300685) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Change In Receivables?

Amoy Diagnostics Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Amoy Diagnostics Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Amoy Diagnostics Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-11 Mil. It means Amoy Diagnostics Co's Accounts Receivable increased by ¥11 Mil from Dec. 2022 to Dec. 2023 .

Amoy Diagnostics Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥504 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Amoy Diagnostics Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 197.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amoy Diagnostics Co's liquidation value for the three months ended in Mar. 2024 was ¥1,280 Mil.


Amoy Diagnostics Co Change In Receivables Historical Data

The historical data trend for Amoy Diagnostics Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Change In Receivables Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.33 -80.67 -132.32 25.91 -10.57

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Amoy Diagnostics Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amoy Diagnostics Co  (SZSE:300685) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amoy Diagnostics Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=504.359/233.289*91
=197.28

2. In Ben Graham's calculation of liquidation value, Amoy Diagnostics Co's accounts receivable are only considered to be worth 75% of book value:

Amoy Diagnostics Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1088.874-202.778+0.75 * 504.359+0.5 * 31.527
=1,280

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amoy Diagnostics Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines